Cardiovascular Effects of Cancer Therapy

  • M. Jacob Adams
  • Sarah A. Duffy
  • Louis S. Constine
  • Steven E. Lipshultz
Part of the Pediatric Oncology book series (PEDIATRICO)


Clin Oncol Sarcoplasmic Reticulum Radiat Oncol Biol Phys Childhood Cancer Childhood Cancer Survivor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mertens AC, Yasui Y, Neglia JP et al. (2001) Late mortality experience in 5-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 19:3163–3172PubMedGoogle Scholar
  2. 2.
    Moller TR, Garwicz S, Barlow L et al. (2001) Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 19:3173–3181PubMedGoogle Scholar
  3. 3.
    Clark EB (1990) Growth, morphogenesis, and function: the dynamics of heart development. In: Moller JH, Neal WA, Lock JE (eds) Fetal, neonatal, and infant heart disease. Appleton-Century-Crofts, New YorkGoogle Scholar
  4. 4.
    Clark EB (1989) Effect of increased ventricular pressure on ventricular growth in stage 21 chick embryo. Am J Physiol 257:1455–1461Google Scholar
  5. 5.
    Fishman NH et al. (1978) Models of congenital heart disease in fetal lambs. Circulation 58:354–364PubMedGoogle Scholar
  6. 6.
    Kim DH et al. (1989) Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesicles. J Mol Cell Cardiol 21:433–436CrossRefPubMedGoogle Scholar
  7. 7.
    Pratt CB, Ransom JL, Evans WE (1978) Age-related Adriamycin cardiotoxicity in children. Cancer Treat Rep 62:1381–1385PubMedGoogle Scholar
  8. 8.
    Billingham ME, Bristow MR, Glatstein E et al. (1977) Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1:17–23PubMedGoogle Scholar
  9. 9.
    Billingham ME et al. (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62:865–872PubMedGoogle Scholar
  10. 10.
    Ewer MS et al. (1984) A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 2:112–117PubMedGoogle Scholar
  11. 11.
    Lipshultz SE, Colan SD, Gelber RD et al. (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808–815PubMedGoogle Scholar
  12. 12.
    Braverman AC et al. (1991) Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 9:1215–1223PubMedGoogle Scholar
  13. 13.
    Mills BA, Roberts RW (1979) Cyclophosphamide-induced cardiomyopathy. Cancer 43:223–226Google Scholar
  14. 14.
    Gottdiener JS et al. (1981) Cardiotoxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 141:753–763CrossRefPubMedGoogle Scholar
  15. 15.
    O'Connell TX, Berenbaum MC (1974) Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Res 34:1586–1691PubMedGoogle Scholar
  16. 16.
    Watts RG (1991) Severe and fatal anthracycline cardiotoxicity at cumulative doses below 400 mg/m2: evidence for enhanced toxicity with multiagent chemotherapy. Am J Hematol 36:217–218PubMedGoogle Scholar
  17. 17.
    Friedman HS et al. (1990) Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res 50:2455–2462PubMedGoogle Scholar
  18. 18.
    Simbre VC, Adams MJ, Deshpande SS et al. (2001) Cardiomyopathy caused by antineoplastic therapies. Curr Treat Options Cardiovasc Med 3:493–505PubMedGoogle Scholar
  19. 19.
    Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents. Drug Safety 22:263–302PubMedGoogle Scholar
  20. 20.
    Leach J (1943) Effect of roentgen therapy on the heart. Arch Intern Med 72:715–745Google Scholar
  21. 21.
    Stewart JR, Fajardo LF (1984) Radiation-induced heart disease: an update. Prog Cardiovasc Dis 27:173–194CrossRefPubMedGoogle Scholar
  22. 22.
    Stewart JR, Fajardo LF, Gillette SM et al. (1995) Radiation injury to the heart. Int J Radiat Oncol Biol Phys 31:1205–1211CrossRefPubMedGoogle Scholar
  23. 23.
    Fajardo LF, Stewart JR, Cohn KE (1968) Morphology of radiation-induced heart disease. Arch Pathol 86:512–519PubMedGoogle Scholar
  24. 24.
    Chello M, Mastroroberto P, Romano R et al. (1996) Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis. Cardiovasc Surg 4:222–226CrossRefPubMedGoogle Scholar
  25. 25.
    McEniery PT, Dorosti K, Schiavone W et al. (1987) Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Card 60:1020–1024CrossRefPubMedGoogle Scholar
  26. 26.
    King V, Constine LS, Clark D et al. (1996) Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys 36:881–889CrossRefPubMedGoogle Scholar
  27. 27.
    Veinot JP, Edwards WD (1996) Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 27:766–773CrossRefPubMedGoogle Scholar
  28. 28.
    Fajardo LF (1977) Radiation-induced coronary artery disease. Chest 71:563–564PubMedGoogle Scholar
  29. 29.
    Corn BW, Trock B, Goodman R (1990) Irradiation-related ischemic heart disease. J Clin Oncol 8:741–750PubMedGoogle Scholar
  30. 30.
    Adams MJ, Lipshultz SE, Schwartz C et al. (2003) Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol 13:346–356CrossRefPubMedGoogle Scholar
  31. 31.
    Brosius FC, Waller BF, Roberts WC (1981) Radiation heart disease. Analysis of 16 young (aged 15–33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 70:519–530CrossRefPubMedGoogle Scholar
  32. 32.
    Carlson RG, Mayfield W, Normann S et al. (1991) Radiation-associated valvular disease. Chest 99:538–545PubMedGoogle Scholar
  33. 33.
    Steinherz LJ, Wexler LH (1998) The prevention of anthracycline cardiomyopathy. Prog Pediatr Cardiol 8:97–108CrossRefGoogle Scholar
  34. 34.
    Jemal A, Thomas A, Murray T et al. (2002) Cancer statistics. CA 52:23–47PubMedGoogle Scholar
  35. 35.
    Krischer JP, Epstein S, Cuthbertson DD et al. (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group. J Clin Oncol 15:1544–1552PubMedGoogle Scholar
  36. 36.
    Giantris A, Abdurrahman L, Hinkle A et al. (1998) Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 27:53–68PubMedGoogle Scholar
  37. 37.
    Von Hoff DD, Layard MW, Basa P et al. (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717PubMedGoogle Scholar
  38. 38.
    Praga C, Beretta G, Vigo PL et al. (1979) Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Trt Rep 63:827–834Google Scholar
  39. 39.
    Lipshultz SE, Sallan SE (1993) Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol 11:1199–1203PubMedGoogle Scholar
  40. 40.
    Lipshultz SE, Sanders SP, Goorin A (1994) Monitoring for anthracycline cardiotoxicity. Pediatrics 93:433–437PubMedGoogle Scholar
  41. 41.
    Lefrak EA, Pitha J, Rosenheim S et al. (1973) A clinicopathologic analysis of adriamycin toxicity. Cancer 32:302–314PubMedGoogle Scholar
  42. 42.
    Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25:72–85PubMedGoogle Scholar
  43. 43.
    Steinherz LJ, Steinherz PG, Tan CT et al. (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672–1677CrossRefPubMedGoogle Scholar
  44. 44.
    Ali MK, Ewer MS, Gibbs HR et al. (1994) Late doxorubicin-associated cardiotoxicity in children: the possible role of intercurrent viral infection. Cancer 74:182–188PubMedGoogle Scholar
  45. 45.
    Steinherz LJ, Steinherz PG, Tan G (1995) Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 24:352–361PubMedGoogle Scholar
  46. 46.
    Lipshultz SE, Vlach SA, Lipsitz SR, Sallen SE, Schwartz ML, Colan SD. Cardiac changes associated with growth hormone therapy in children treated with anthracycline. (Pediatrics. In press, 2004)Google Scholar
  47. 47.
    Davis LE, Brown CE (1988) Peripartum heart failure in a patient treated previously with doxorubicin. Obstet Gynecol 71:506–508 (abstract)PubMedGoogle Scholar
  48. 48.
    Lipshultz SE, Lipsitz SR, Mone SM et al. (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738–1743CrossRefPubMedGoogle Scholar
  49. 49.
    Larsen RL, Barber G, Heise CT et al. (1992) Exercise assessment of cardiac function in children and young adults before and after bone marrow transplantation. Pediatrics 89:722–729PubMedGoogle Scholar
  50. 50.
    Larsen RL, Jakacki RI, Vetter VL et al. (1992) Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 70:73–77CrossRefPubMedGoogle Scholar
  51. 51.
    Green DM, Grigoriev YA, Nan B et al. (2001) Congestive heart failure after treatment for Wilms’ Tumor: A report from the National Wilms'Tumor Study Group. J Clin Oncol 19:1926–1934PubMedGoogle Scholar
  52. 52.
    Schwartz CL, Hobbie W, Truesdell S et al. (1993) Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 11:1906–1910PubMedGoogle Scholar
  53. 53.
    Jakacki RI, Larsen RL, Barber G, Goldwein JW, Silber JH. Cardiac function following cardiotoxic therapy during childhood assessing the damage. In Cardiac Toxicity after Treatment for Childhood Cancer. Eds. Bricker JT, Green DM, D'Angio GJ. NY, NY: John Wiley & Sons, 1993:87–94Google Scholar
  54. 54.
    Bender KS et al. (1984) QT interval prolongation associated with anthracycline cardiotoxicity. J Pediatr 105:442–444PubMedGoogle Scholar
  55. 55.
    Bristow MR, Mason JW, Billingham ME et al. (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 88:168–175PubMedGoogle Scholar
  56. 56.
    Cortes EP, Lutman G, Wanka J et al. (1975) Adriamycin (NSC-123127) cardiotoxicity: a clinicopathologic correlation. Cancer Chemother Rep 6:215–225Google Scholar
  57. 57.
    Dearth J, Osborn R, Wilson E et al. (1984) Anthracycline-induced cardiomyopathy in children: a report of six cases. Med Pediatr Oncol 12:54–58PubMedGoogle Scholar
  58. 58.
    Von Hoff DD, Rozencweig M, Layard M et al. (1977) Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 62:200–208CrossRefPubMedGoogle Scholar
  59. 59.
    Postma A, Bink-Boelkens MTE, Beaufort-Krol GCM et al. (1996) Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol 26:230–237CrossRefPubMedGoogle Scholar
  60. 60.
    Nysom K, Holm K, Lipsitz SR et al. (1998) The relation between cumulative anthracycline dose and late cardiotoxicity in survivors of childhood leukemia. J Clin Oncol 16:545–550PubMedGoogle Scholar
  61. 61.
    Silber JH, Jakacki RI, Larsen RL et al. (1993) Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 21:477–479PubMedGoogle Scholar
  62. 62.
    Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6:1321–1327PubMedGoogle Scholar
  63. 63.
    Lipshultz SE, Giantris AL, Lipsitz SR et al. (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol. J Clin Oncol 20:1677–1682CrossRefPubMedGoogle Scholar
  64. 64.
    Levitt GA, Dorup I, Sorenson K, Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? Brit J Hematol 124:463–468Google Scholar
  65. 65.
    Krischer JP, Cuthbertson DD, Epstein S et al. (1998) Risk factors for early anthracycline clinical cardiotoxicity in children: the Pediatric Oncology Group experience. Prog Pediatr Cardiol 8:83–90CrossRefGoogle Scholar
  66. 66.
    Pohjola-Sintonen S, Totterman KJ, Kupari M (1990) Sick sinus syndrome as a complication of mediastinal radiation therapy. Cancer 65:2494–2496PubMedGoogle Scholar
  67. 67.
    Adams MJ, Lipsitz SR, Colan SD et al. (2004) Cardiovascular status in long-term survivors of Hodgkin's Disease treated with chest rediotherapy. J Clin Oncol 22:3139–3148CrossRefPubMedGoogle Scholar
  68. 68.
    Lee CK, Aeppli D, Nierengarten ME (2000) The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 48:169–179CrossRefPubMedGoogle Scholar
  69. 69.
    Mauch P, Kalish LA, Marcus KC et al. (1995) Long-term survival in Hodgkin's disease: relative impact of mortality, second tumors, infection and cardiovascular disease. Cancer J Sci Am 1:33–42PubMedGoogle Scholar
  70. 70.
    Hancock SL, Tucker MA, Hoppe RT (1993) Factors affecting late mortality from heart disease after treatment for Hodgkin's disease. JAMA 270:1949–1955CrossRefPubMedGoogle Scholar
  71. 71.
    Hancock SL, Donaldson SS, Hoppe RT (1993) Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 11:1208–1215PubMedGoogle Scholar
  72. 72.
    Reinders JG, Heijmen BJ, Olofsen-van Acht MJ et al. (1999) Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol 51:35–42CrossRefPubMedGoogle Scholar
  73. 73.
    Glanzmann C, Kaufmann P, Jenni R et al. (1998) Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 46:51–62CrossRefPubMedGoogle Scholar
  74. 74.
    Radwaner BA, Geringer B, Goldman AM et al. (1987) Left main coronary artery stenosis following mediastinal irradiation. Am J Med 82:1017–1020CrossRefPubMedGoogle Scholar
  75. 75.
    Rodgers DL (1976) Precocious myocardial infarction after radiation treatment for Hodgkin's disease. Chest 70:675–677PubMedGoogle Scholar
  76. 76.
    Totterman KJ, Pesonen E, Siltanen P (1983) Radiation related chronic heart disease. Chest 83:875–878PubMedGoogle Scholar
  77. 77.
    Angelini A, Benciolini P, Thiene G (1985) Radiation-induced coronary obstructive atherosclerosis and sudden death in a teenager. Int J Cardiol 9:371–373CrossRefPubMedGoogle Scholar
  78. 78.
    Boivin J-F, Hutchison G, Lubin J et al. (1992) Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 69:1241–1247PubMedGoogle Scholar
  79. 79.
    Pohjola-Sintonen S, Totterman KJ, Salmo M et al. (1987) Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin's disease. Cancer 60:31–37PubMedGoogle Scholar
  80. 80.
    Carmel RJ, Kaplan HS (1976) Mantle irradiation in Hodgkin's disease. Cancer 37:2813–2815PubMedGoogle Scholar
  81. 81.
    Martin RG, Ruckdeschel J, Chang P et al. (1975) Radiationrelated pericarditis. Am J Cardiol 35:216–220CrossRefPubMedGoogle Scholar
  82. 82.
    Arsenian MA (1991) Cardiovascular sequelae of therapeutic thoracic radiation. Prog Cardiovasc Dis 33:299–311CrossRefPubMedGoogle Scholar
  83. 83.
    Applefeld MM (1981) The late appearance of chronic pericardial disease in patients treated by radiotherapy for Hodgkin's disease. Ann Intern Med 94:338–341PubMedGoogle Scholar
  84. 84.
    Byhardt R, Brace K, Ruckdeschel JC et al. (1975) Dose and treatment factors in radiation-related pericardial effusion associated with the mantle technique for Hodgkin's disease. Cancer 35:795–802PubMedGoogle Scholar
  85. 85.
    Cameron EH, Lipshultz SE, Tarbell NJ et al. (1998) Cardiovascular disease in long-term survivors of pediatric Hodgkin's disease. Prog Pediatr Cardiol 8:139–144CrossRefGoogle Scholar
  86. 86.
    Tolba KA, Deliargyris EN (1999) Cardiotoxicity of cancer therapy. Cancer Invest 17:408–422PubMedGoogle Scholar
  87. 87.
    Burns RJ, Bar Shlomo BZ, Druck MN et al. (1983) Detection of radiation cardiomyopathy by gated radionuclide angiography. Am J Med 74:297–301CrossRefPubMedGoogle Scholar
  88. 88.
    Constine LS, Schwartz RG, Savage D et al. (1997) Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease. Int J Radiat Oncol Biol Phys 39:897–906CrossRefPubMedGoogle Scholar
  89. 89.
    Hardenbergh PH, Munley MT, Bentel GC et al. (2001) Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys 49:1023–1028CrossRefPubMedGoogle Scholar
  90. 90.
    Gyenes G, Fornander T, Carlens P et al. (1996) Myocardial damage in breast cancer patients treated with adjuvant radiotherapy: a prospective study. Int J Radiat Oncol Biol Phys 36:899–905CrossRefPubMedGoogle Scholar
  91. 91.
    Adams MJ, Hardenbergh P, Constine LS et al. (2003) Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 45:55–75PubMedGoogle Scholar
  92. 92.
    Merrill J, Geco FA, Zimber H et al. (1975) Adriamycin and radiation: synergistic cardiotoxicity. Ann Intern Med 82:122–123 (abstract)Google Scholar
  93. 93.
    Kinsella TJ, Ahmann DL, Giuliani ER et al. (1979) Adriamycin toxicity in stage IV breast cancer: possible enhancement with prior left chest radiation therapy. Int J Radiat Oncol Biol Phys 5:1979–2002Google Scholar
  94. 94.
    Fajardo LF, Eltringham JR, Stewart JR (1976) Combined cardiotoxicity of adriamycin and x-radiation. Lab Invest 34:86–96PubMedGoogle Scholar
  95. 95.
    Eltringham JR, Fajardo LF, Stewart JR et al. (1979) Investigation of cardiotoxicity in rabbits from adriamycin and fractionated cardiac irradiation: preliminary results. Front Radiat Ther Oncol 13:21–35Google Scholar
  96. 96.
    Pihkala J, Saarinen U, Lundstrom U et al. (1996) Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 32A:97–103CrossRefPubMedGoogle Scholar
  97. 97.
    Leonard GT, Green DM, Spangenthal EL et al. (2000) Cardiac mortality and morbidity after treatment for Hodgkin disease during childhood and adolescence. Pediatr Res 47:46A (abstract)Google Scholar
  98. 98.
    Shapiro CL, Hardenbergh PH, Gelman R et al. (1998) Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 16:3493–3501PubMedGoogle Scholar
  99. 99.
    Glanzmann C, Huguenin P, Lutolf UM et al. (1994) Cardiac lesions after mediastinal radiation for Hodgkin's disease. Radiother Oncol 30:43–54CrossRefPubMedGoogle Scholar
  100. 100.
    Gustavsson A, Eskilsson J, Landberg T et al. (1990) Late cardiac effects after mantle radiation in patients with Hodgkin's disease. Ann Oncol 1:355–363PubMedGoogle Scholar
  101. 101.
    Lund MB, Ihlen H, Voss BM et al. (1996) Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. Heart 75:591–595PubMedGoogle Scholar
  102. 102.
    Adams MJ, Lipsitz SR, Colan SD et al. (2004) Cardiovascular status in long-term survivors of Hodgkin's Disease treated with chest rediotherapy. J Clin Oncol 22:3139–3148CrossRefPubMedGoogle Scholar
  103. 103.
    Orzan F, Brusca A, Gaita F et al. (1993) Associated cardiac lesions in patients with radiation-induced complete heart block. Int J Cardiol 39:151–156CrossRefPubMedGoogle Scholar
  104. 104.
    Slama MS, Le Guludec D, Sebag C et al. (1991) Complete atrioventricular block following mediastinal irradiation: a report of six cases. PACE 14:1112–1118PubMedGoogle Scholar
  105. 105.
    Hancock SL (1998) Cardiac toxicity after cancer therapy. Research issues in Cancer Survivorship Meeting, 3 Mar 1998. National Cancer Institute, Bethesda, MarylandGoogle Scholar
  106. 106.
    Childrens Oncology Group (2004) Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. (electronic citation)Google Scholar
  107. 107.
    Steinherz LJ, Graham T, Hurwitz R et al. (1992) Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the Children's Cancer Study Group. Pediatrics 89:942–949PubMedGoogle Scholar
  108. 108.
    Lipshultz SE, Colan SD (1993) The use of echocardiography and Holter monitoring in the assessment of anthracycline-treated patients, Cardiac Toxicity after Treatment for Childhood Cancer. Wiley-Liss, New York, pp 45–62Google Scholar
  109. 109.
    Colan SD, Borow KM, Neuman A (1984) Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load independent index of myocardial contractility. J Am Coll Cardiol 4:715–724PubMedGoogle Scholar
  110. 110.
    Weesner KM (1991) Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 68:435–438PubMedGoogle Scholar
  111. 111.
    Mancini DM, Eisen H, Kussmaul W et al. (1991) Value of peak exercise oxygen consumption for the optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83:778–786PubMedGoogle Scholar
  112. 112.
    Orzan F, Brusca A, Conte MR et al. (1993) Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J 69:496–500PubMedGoogle Scholar
  113. 113.
    Adams MJ, Constine LS, Lipshultz SE (2001) Radiation. In: Crawford MH, DiMarco JP (eds) Cardiology. Mosby International, London, pp 8.15.1–8Google Scholar
  114. 114.
    Speyer JL, Green MD, Kramer E et al. (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745–752PubMedGoogle Scholar
  115. 115.
    Swain SM, Whaley FS, Gerber MC et al. (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318–1332PubMedGoogle Scholar
  116. 116.
    Speyer JL, Green MD, Zeleniuch-Jacquotte A et al. (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117–127PubMedGoogle Scholar
  117. 117.
    Bu'Lock FA, Gabriel HM, Oakhill A et al. (1993) Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 70:185–188PubMedGoogle Scholar
  118. 118.
    Wexler LH, Andrich MP, Venzon D et al. (1996) Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14:362–372PubMedGoogle Scholar
  119. 119.
    Lipshultz SE, Rifai N, Dalton VM et al. (2004) The effect of Dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. New Engl J Med 2004; 351:145–153CrossRefPubMedGoogle Scholar
  120. 120.
    Schwartz CL, Tebbi CK, London WB et al. (2003) Enhanced toxicity in pediatric Hodgkin disease (HD) patients treated with DBVE or DBVE-PC and Dexrazoxane (DXR). Blood 102:11–16 (abstract)CrossRefGoogle Scholar
  121. 121.
    Hinkle AS, Truesdell SC, Proukou CB et al. (1998) Cardiotoxicity related to cancer therapy. Prog Pediatr Cardiol 8:145–155CrossRefGoogle Scholar
  122. 122.
    Heart Failure Guideline Panel (1994) Heart Failure: evaluation and care of patients with left ventricular systolic dysfunction. Clinical Practice Guideline #11. US Department of Health and Human Services, Agency for Health Care Policy and Research (report)Google Scholar
  123. 123.
    Guidelines for the evaluation and management of heart failure (1995) Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 92:2764–2784Google Scholar
  124. 124.
    Hunt SA, Baker DW, Chin MH et al. (2001) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in Collaboration With the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 104:2996–3007PubMedGoogle Scholar
  125. 125.
    Miller TL, Horgan S, Lipshultz SE. Exercise rehabilitation of pediatric patients with cardiovascular disease. Prog Pediatr Cardiol. (In press 2004)Google Scholar
  126. 126.
    Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486–2497Google Scholar
  127. 127.
    Lipshultz SE, Lipsitz SR, Sallan SE et al. (2003) Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence: in reply (letter). J Clin Oncol 21:3377–3378CrossRefPubMedGoogle Scholar
  128. 128.
    Lipshultz SE, Colan SD (2004) Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol 22:769–773CrossRefPubMedGoogle Scholar
  129. 129.
    Pitt B, Zannad F, Remme WJ et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators (comment). N Engl J Med 341:709–717CrossRefPubMedGoogle Scholar
  130. 130.
    Noori A, Lindenfield J, Wolfel E et al. (2000) Beta-blockade in adriamycin-induced cardiomyopathy. J Cardiac Failure 6:115–119Google Scholar
  131. 131.
    Pfeffer MA, Braunwald E, Moye LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669–677PubMedGoogle Scholar
  132. 132.
    Lipshultz SE, Lipsitz SR, Sallan SE et al. (2002) Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 20:4517–4522CrossRefPubMedGoogle Scholar
  133. 133.
    Packer M, Bristow MR, Cohn JN et al. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349–1355CrossRefPubMedGoogle Scholar
  134. 134.
    Woodley SL, Gilbert EM, Anderson JL et al. (1991) Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 84:2426–2441PubMedGoogle Scholar
  135. 135.
    Fisher ML, Gottlieb SS, Plotnick GD et al. (1994) Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 23:843–950Google Scholar
  136. 136.
    Olsen SL, Gilbert EM, Renlund DG et al. (1995) Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Col Cardiol 25:1225–1231CrossRefGoogle Scholar
  137. 137.
    Waagstein F, Bristow MR, Swedberg K (1993) Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441–1446CrossRefPubMedGoogle Scholar
  138. 138.
    Dillon TA, Sullivan M, Schatzlein MH et al. (1991) Cardiac transplantation in patients with preexisting malignancies. Transplantation 52:82–85PubMedGoogle Scholar
  139. 139.
    Stevenson LW, Warner SL, Steimle AE et al. (1994) The impending crisis awaiting cardiac transplantation. Modeling a solution based on selection. Circulation 89:450–457PubMedGoogle Scholar
  140. 140.
    Herman EH, Zhang J, Lipshultz SE et al. (1999) Correlation between serum levels of cardiac troponin-T and the severity of chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237–2243PubMedGoogle Scholar
  141. 141.
    Hicks GL Jr (1992) Coronary artery operation in radiation-associated atherosclerosis: long-term follow-up. Ann Thorac Surg 53:670–674PubMedGoogle Scholar
  142. 142.
    Gharagozloo F, Clements I, Mullany C (1992) Use of the internal mammary artery for myocardial revascularization in a patient with radiation-induced coronary artery disease. Mayo Clin Proc 67:1081–1084PubMedGoogle Scholar
  143. 143.
    Handa N, McGregor CG, Danielson GK et al. (1999) Coronary artery bypass grafting in patients with previous mediastinal radiation therapy. J Thorac Cardiovasc Surg 117:1136–1142PubMedGoogle Scholar
  144. 144.
    Van Son JA, Noyez L, van Asten W (1992) Use of internal mammary artery in myocardial revascularization after mediastinal irradiation. J Thorac Cardiovasc Surg 104:1539–1544PubMedGoogle Scholar
  145. 145.
    Reber D, Birnbaum DE, Tollenaere P (1995) Heart diseases following mediastinal irradiation: surgical management. Eur J Cardiothorac Surg 9:202–205CrossRefPubMedGoogle Scholar
  146. 146.
    Mittal S, Berko B, Bavaria J et al. (1996) Radiation-induced cardiovascular dysfunction. Am J Cardiol 78:114–115CrossRefPubMedGoogle Scholar
  147. 147.
    Morton DL, Glancy D, Joseph WL et al. (1973) Management of patients with radiation-induced pericarditis with effusion: a note on the development of regurgiation in two of them. Chest 64:291–297PubMedGoogle Scholar
  148. 148.
    Huettemann E, Junker T, Chatzinikolaou KP et al. (2004) The influence of anthracycline therapy on cardiac function during anesthesia. Anesth Analg 98:941–947CrossRefPubMedGoogle Scholar
  149. 149.
    Kodama K, Fujiwara S, Yamada M et al. (1996) Profiles of non-cancer disease in atomic bomb survivors. World Health Statistics Quarterly-Rapport Trimestriel de Statistiques Saintaires Mondiales 49:7–16Google Scholar
  150. 150.
    Warda M, Khan A, Massumi A et al. (1983) Radiation-induced valvular dysfunction. J Am Coll Cardiol 2:180–185PubMedGoogle Scholar
  151. 151.
    Shimizu Y, Kato H, Schull W et al. (1992) Studies of mortality of A-bomb survivors: mortality 1950–1985, part 3. Non-cancer mortality based on the revised doses. Radiat Res 130:249–266PubMedGoogle Scholar
  152. 152.
    Shimizu Y, Pierce DA, Preston DL et al. (1999) Studies of mortality of atomic bomb survivors, report 12, part II. Non-cancer mortality: 1950–1990. Radiat Res 152:374–389PubMedGoogle Scholar
  153. 153.
    Perrault DJ, Levy M, Herman JD et al. (1985) Echocardiographic abnormalities following cardiac radiation. J Clin Oncol 3:546–551PubMedGoogle Scholar
  154. 154.
    Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Col Cardiol 2003; 42:743–749CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • M. Jacob Adams
  • Sarah A. Duffy
  • Louis S. Constine
  • Steven E. Lipshultz

There are no affiliations available

Personalised recommendations